Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells

At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezom...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Margot S.F. Roeten, Johan van Meerloo, Zinia J. Kwidama, Giovanna ter Huizen, Wouter H. Segerink, Sonja Zweegman, Gertjan J.L. Kaspers, Gerrit Jansen, Jacqueline Cloos
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-03-01
coleção:	Cells
Assuntos:	leukemia proteasome proteasome inhibitor ixazomib BTZ resistance drug resistance
Acesso em linha:	https://www.mdpi.com/2073-4409/10/3/665
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!